{"id":"NCT03162796","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-24","primaryCompletion":"2019-03-14","completion":"2019-11-18","firstPosted":"2017-05-22","resultsPosted":"2020-10-14","lastUpdate":"2021-02-03"},"enrollment":383,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Psoriatic"],"interventions":[{"type":"DRUG","name":"Guselkumab","otherNames":["CNTO 1959"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1: Guselkumab","type":"EXPERIMENTAL"},{"label":"Group 2: Guselkumab and Placebo","type":"EXPERIMENTAL"},{"label":"Group 3: Placebo Followed by Guselkumab","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active Psoriatic Arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo","deltaMin":22.2,"sd":null},{"arm":"Guselkumab 100 mg q8w","deltaMin":52,"sd":null},{"arm":"Guselkumab 100 mg q4w","deltaMin":59.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG002","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":95,"countries":["United States","Australia","Canada","Czechia","Germany","Hungary","Malaysia","Poland","Russia","South Korea","Spain","Taiwan","Ukraine"]},"refs":{"pmids":["39320583","39261446","38765190","37906417","36995469","36642439","35768650","35766811","35296534","34261541","34011674","33934076","33822898","32178765"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":126},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Alanine Aminotransferase Increased","Aspartate Aminotransferase Increased","Enthesopathy"]}}